Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Court overturns Trump officials' contempt order, a legal victory for the administration amid ongoing tensions between branches over immigration enforcement.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Court overturns Trump officials' contempt order, a legal victory for the administration amid ongoing tensions between branches over immigration enforcement.